Avinger Inc.

0.47
-0.13 (-21.40%)
At close: Feb 14, 2025, 3:59 PM

Company Description

Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and internationally.

It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures.

The company's lumivascular products comprise Lightbox imaging consoles, as well as the Ocelot family of catheters, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients.

In addition, its first-generation chronic total occlusion (CTO)-crossing catheters, Wildcat and Kittycat 2, which employs a proprietary design that uses a rotational spinning technique allowing the physician to switch between passive and active modes when navigating across a CTO.

Further, the company develops IMAGE-BTK for the treatment of PAD lesions below-the-knee.

It markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists.

Avinger, Inc. was incorporated in 2007 and is headquartered in Redwood City, California.

Avinger Inc.
Avinger Inc. logo
Country United States
IPO Date Jan 30, 2015
Industry Medical - Instruments & Supplies
Sector Healthcare
Employees 68
CEO Nabeel P. Subainati CPA

Contact Details

Address:
400 Chesapeake Drive
Redwood City, California
United States
Website https://avinger.com

Stock Details

Ticker Symbol AVGR
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001506928
CUSIP Number 053734604
ISIN Number US0537348775
Employer ID 20-8873453
SIC Code 3841

Key Executives

Name Position
Dr. Jaafer Golzar FACC, M.D. Chief Medical Officer
Nabeel P. Subainati CPA Vice President of Finance, Principal Financial Officer & Principal Accounting Officer
Philip R. Preuss Chief Commercial Officer

Latest SEC Filings

Date Type Title
Feb 14, 2025 SCHEDULE 13G/A [Amend] Filing
Feb 10, 2025 8-K Current Report
Feb 05, 2025 8-K Current Report
Jan 24, 2025 4 Filing
Jan 24, 2025 4 Filing
Jan 24, 2025 4 Filing
Jan 24, 2025 DEFA14A Filing
Jan 24, 2025 8-K Current Report
Jan 13, 2025 DEFR14A Filing
Jan 13, 2025 DEFA14A Filing